Literature DB >> 15980455

GraBCas: a bioinformatics tool for score-based prediction of Caspase- and Granzyme B-cleavage sites in protein sequences.

Christina Backes1, Jan Kuentzer, Hans-Peter Lenhof, Nicole Comtesse, Eckart Meese.   

Abstract

Caspases and granzyme B are proteases that share the primary specificity to cleave at the carboxyl terminal of aspartate residues in their substrates. Both, caspases and granzyme B are enzymes that are involved in fundamental cellular processes and play a central role in apoptotic cell death. Although various targets are described, many substrates still await identification and many cleavage sites of known substrates are not identified or experimentally verified. A more comprehensive knowledge of caspase and granzyme B substrates is essential to understand the biological roles of these enzymes in more detail. The relatively high variability in cleavage site recognition sequence often complicates the identification of cleavage sites. As of yet there is no software available that allows identification of caspase and/or granzyme with cleavage sites differing from the consensus sequence. Here, we present a bioinformatics tool 'GraBCas' that provides score-based prediction of potential cleavage sites for the caspases 1-9 and granzyme B including an estimation of the fragment size. We tested GraBCas on already known substrates and showed its usefulness for protein sequence analysis. GraBCas is available at http://wwwalt.med-rz.uniklinik-saarland.de/med_fak/humangenetik/software/index.html.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15980455      PMCID: PMC1160194          DOI: 10.1093/nar/gki433

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


INTRODUCTION

Caspases are enzymes orchestrating the cellular pathways leading to apoptosis and inflammatory signals. Besides these functions they are supposed to be involved in other cellular processes, such as development, cell cycle, cell proliferation, cell migration and receptor internalization (1,2). Caspases are cysteine proteases with specificity for an aspartic acid residue at position P1 of the substrate. This primary specificity is shared by the serine protease granzyme B, which induces cytotoxic T lymphocyte-mediated target cell DNA fragmentation and apoptosis (3,4). Granzyme B-mediated cleavage also plays a role in induction of autoimmunity (5). To date, at least 14 mammalian caspases can be grouped into three classes based on their substrate specificities. Group I consisting of caspases -1, -4, -5 (-14 and murine -11 and -12) cleaves the substrate sequence (W/L)EHD, group II (caspases -2, -3, -7) cleaves the DEXD motif and group III (caspase -6, -8, -9, -10) preferentially cleaves the (L/V)E(T/H)D sequence (6,7). Caspases of group I play an important role in the generation of inflammatory signals and in the immune regulation. Caspases -8, -9 and -10 are so-called initiator caspases mainly cleaving and activating procaspases, whereas caspases -3, -6 and -7 as effector caspases cleave numerous cellular proteins. The serine protease granzyme B prefers substrates with sequence IEXD, and is released by cytotoxic lymphocytes to kill virus-infected or tumor cells. Although more than 280 caspase targets are described [for comprehensive review see (8)] many substrates still await identification and many cleavage sites of known substrates are not identified or experimentally verified. Likewise, the identification of granzyme B substrates is still at its infancy. Intracellular substrates of granzyme B include other caspases, mainly caspase 3 (9), ADPRT (ADP-ribosyltransferase 1, PARP) (10), BID (BH3 interacting domain death agonist) (11) and ICAD (DNA fragmentation factor) (12). Notably, the majority of autoantigens in systemic autoimmune diseases are efficiently cleaved by granzyme B (5). A more comprehensive knowledge of caspase and granzyme B substrates is essential to understand the biological roles of these enzymes in more detail. The relatively high variability in cleavage site recognition sequence often complicates the identification of cleavage sites. As of yet there is no software available that allows identification of caspase and/or granzyme cleavage sites differing from the consensus sequence. The PeptidCutter program provided by the ExPasy Server () considers only the preferred peptide substrate sites. A recent tool of Lohmüller et al. (13) is restricted to caspase 3 and cathepsin B and -L substrates. Here, we present a bioinformatics tool GraBCas that provides score-based prediction of potential cleavage sites for the caspases 1–9 and granzyme B including an estimation of the fragment size. We validated our tool by scoring known substrates and demonstrated its usefulness for protein sequence analysis.

MATERIALS AND METHODS

Design of cleavage site scoring matrices

We developed position specific scoring matrices (PSSM) for the endopeptidases granzyme B and caspase 1–9 based on experimentally determined substrate specificities (6). Thornbery et al. (6) determined the substrate specificities using positional scanning synthetic combinatorial libraries. Cleavage was fluorimetrically determined with maximum value annotated with 100 and the values for the remaining amino acids given as percentage of the observed maximum rate. These experimental values provided the basis for creating our PSSM. The values for each amino acid at position Pi are shown in Table 1. For a better readability we decided to set the maximum values to 1000 instead of 100 and adjusted the other values accordingly. For each endopeptidase the scores of the amino acids were entered in a 3 × 20 matrix. The rows of such a matrix correspond to positions P4, P3 or P2 of a possible cleavage site. Each column represents one amino acid and contains the relative frequencies of the amino acid measured in the study of Thornbery et al. (6). We are working with PSSM that can be interpreted as probability matrices. Since probabilities of value 0 should be avoided in such probability-based position scores, all entries of experimental relative frequencies with value 0 were set to 1. The amino acids cysteine and methionine were not part of the study of Thornbery et al. (6). The entries for these amino acids were also set to 1 in Table 1.
Table 1

Scoring matrices for granzyme B and caspases 1–9

Position PiAA of consensus recognition motifCSTPAGNDEQHRKMILVFYW
Granzyme B4I111111111111111000525001211
3E129754115347711981000819111111119
2P175254410005761662414428857654411116963041441616
Caspase 14W148484848161680961612811196288804965761000
3E1357442144242511937410006461875134122132344227218785
2H11443961441801872367210810005472119854108126144126
Caspase 24D11501011101000200111111804008040401
3E1425884168011911910210006801534082211119187646255187153
2H162452835233648961116100032030411441680161680
Caspase 34D14050110120100040110111101201011
3E1306357135785153255100040818717171153153306272255119
2V11437840618211410141964201714224100018215484
Caspase 44W18020814496488028825696481113048482243843521000
3E1187119341191785221100030685117151852041878517
2H11021191194251710222135715310005111595171198510251
Caspase 54W11456156126429898845611128010001545044061000
3E12412112111241000121211112121212121
2H13404253233231851193238510001734127217272153204102
Caspase 64V11448806496166422425648481116563041000804848
3E1484816801616176100014448111161648481648
2H154576187218108181836100054361648486918288216558
Caspase 74D1117781392626100010426391111311313131
3E12213571323511532551000425187851021306221697204204102
2V1164484481281648111620880161704176100016012848
Caspase 84L120830448044896304704448961441115761000720224256144
3E1457504515151801000150451114515105454515
2T11801000216324181267219810830672721720108792180198306
Caspase 94L1198216594576144108414468180126361815761000684252216144
3E18513651851717272100018711911711021192041028551
2H1851361028517175134171000341118717153513451

Amino acid preference distribution for each position Pi was extracted from Thornberry et al. (6) giving the most common amino acid a value of 1000.

Computing the scores of endopeptidase cleavage sites

For computing the score, the GraBCas program screens for tetrapeptides with Asp (D) at their last position (P1) in a given amino acid sequence. Given the tetrapeptide A4A3A2D (≈P4P3P2P1) of a potential cleavage site, its score for a given endopeptidase is computed by multiplying the corresponding matrix entries of A2 at position P2, A3 at position P3 and A4 at position P4. The product is divided by the value (10003) of the product of the consensus recognition motif for normalization and multiplied by 100, yielding a total score between 0 and 100.

Using additional filter options for granzyme B and caspase 3

To improve the power of the prediction we analyzed the amino acid distribution of known granzyme B and caspase 3 cleavage sites at positions P6–P2′ taken from the literature (see also Supplementary Material 1 and 2). For granzyme B we found a preference for V (15×) and I (11×) at position P4, for E (9×) at position P3 and for P (11×) at position P2 in accordance with the results of Thornberry et al. (6). We detected S at position P1′ and G at position P2′, respectively in 9 out of 30 cleavage sites. The result list of the PSSM-based cleavage sites can optionally be filtered with two ‘stringency’ filters that take the occurrence of amino acids at position P2′ into account. We installed a ‘low stringency’ filter that excludes hits with the amino acids C, Q, I, M, V all of which are medium sized or large amino acids. A second ‘high stringency’ filter selects hits with a G at position P2′. The analysis of the 59 cleavage sites of caspase 3 substrate confirmed the preferences for D at P4 (31×), E at P3 (17×) and V at P2 (16×). For P1′ we found an abundance of G (18×) and S (17×) and in lower amount A (5×) and N (4×). As for the granzyme B prediction, two additional ‘stringency’ filters for the prediction of caspase 3 cleavage sites are available. The ‘high stringency’ filter screens the predicted hits for occurrences of G, S, A or N at position P1′, and the ‘low stringency’ filter screens for absence of R, E, H, K, Q, I, L, M, F, W and Y at this position.

GraBCas software tool

The GraBCas program was written in Java™ and is available as an application or as an applet. Both are available at . If your browser does not support Java™ you need to install the Java Runtime Environment (JRE) 1.4.x, which can be downloaded at . The graphical user interface is easy to use. There are several register cards for each endopeptidase and one register card presenting the input form, where the amino acid sequence can be pasted and a cutoff for the PSSM scores can be chosen. After pressing the OK-button in the input form, the program calculates the scores of potential cleavage sites for all endopeptidases and presents them in the corresponding register card sorted with the highest scoring sites on top. The user can open an additional window for viewing the positions of the predicted cleavage sites within the amino acid sequence. The window also shows the fragment length and size in kDa (0.11 kDa per amino acid) of the predicted fragments. As described above, for caspase 3 and granzyme B additional filter options are available in their register cards. The two filter types for these enzymes, a ‘high-stringency’ and a ‘low-stringency’ filter, are based on the extended substrate specificity. For granzyme B the amino acids at position P2′ were taken into account in addition to the positions P4–P1. For caspase 3, amino acids at position P1′ are evaluated.

Sensitivity–specificity plots

For determining the specificity and sensitivity of the GraBCas predictions we used the known cleavage sites of granzyme B (4–6,9–12) summarized in Table 2 and the known non-substrates of granzyme B (5) presented in Table 4. Due to the lack of information on known non-substrates for caspase 3 the sensitivity–specificity plot could only be calculated for granzyme B (Figure 1).
Table 2

Analysis of cleavage sites of known granzyme B substrates with GraBCas

Granzyme B substrateAcc_numberKnown cleavage siteScore by GraBCasP6–P2′ of cleavage site
AARS: alanyl-tRNA synthetaseNP_001596VADP (632)7,65SLVAPDRL
ADPRT: ADP-ribosyltransferase (NAD+; poly (ADP-ribose) polymerase)NP_001609VDPD (536)9,9AAVDPDSG
BID: BH3 interacting domain death agonistNP_001187IEAD (75)57,6GRIEADSE
CASP3: caspase 3, apoptosis-related cysteine proteaseNP_004337IETD (175)54,4CGIETDSG
CASP7: caspase 7, apoptosis-related cysteine proteaseNP_001218IQAD (198)4,6656DGIQADSG
CENPB: centromere protein B, 80 kDaNP_001801VDSD (457)7,4448GDVDSDEE
CHD4: chromodomain helicase DNA binding protein 4NP_001264VDPD (1312)9,9ESVDPDYW
DFFA: DNA fragmentation factor, 45 kDa, alpha polypeptideNP_004392DETD (117)0,0544MEVTGDAG
DFFA: DNA fragmentation factor, 45 kDa, alpha polypeptideNP_004392VTGD (6)0,0432DVDETDSG
FBL: fibrillarinNP_001427VGPD (184)23,85DIVGPDGL
FLNA: filamin A, alpha (actin binding protein 280)NP_001447?11,4048TEIDQDKY
G22P1: thyroid autoantigen 70 kDa (Ku antigen)NP_001460ISSD (79)22,3344KIISSDRD
GRIA3: glutamate receptor, ionotrophic, AMPA 3NP_000819ISND (416)18,5328QQISNDSA
HARS: histidyl-tRNA synthetaseNP_002100LGPD (48)2,4804AQLGPDES
IARS: isoleucine-tRNA synthetaseNP_002152VTPD (983)2,7LDVTPDQS
L4 100K [Human adenovirus C]AAQ19301IEQD (48)57,6VIIEQDPG
MKI67: antigen identified by monoclonal antibody Ki-67NP_002408VCTD (1481)0,0272TPVCTDKP
NUMA1: nuclear mitotic apparatus protein 1NP_006176VATD (1705)4,1616FQVATDAL
PMS1: PMS1 postmeiotic segregation increased 1NP_000525ISAD (496)17,1072SEISADEW
PMS2: PMS2 postmeiotic segregation increased 2NP_000526VEKD (493)0,05AEVEKDSG
PMSCL2: polymyositis/scleroderma autoantigen 2, 100 kDaNP_002676VEQD (252)28,8QQVEQDMF
POLR1A: polymerase (RNA) I polypeptide A, 194 kDaNP_056240ICPD (448)0,1SVICPDMY
POLR2A: polymerase (RNA) II (DNA directed) polypeptide A, 220 kDaNP_000928ITPD (370)5,4TVITPDPN
PRKDC: protein kinase, DNA-activated, catalytic polypeptideNP_008835VGPD (2698)23,85KSVGPDFG
SNRP70: small nuclear ribonucleoprotein 70 kDa polypeptide (RNP antigen)NP_003080LGND (409)1,5477696EGLGNDSR
SRP72: signal recognition particle 72 kDaNP_008878VTPD (573)2,7PKVTPDPE
SSB: Sjogren syndrome antigen B (autoantigen La)NP_003133LEED (220)1,4976QKLEEDAE
TOP1: topoisomerase (DNA) INP_003277IEAD (15)57,6SQIEADFR
UBE4B: ubiquitination factor E4B (UFD2 homolog, yeast)NP_006039VDVD (123)3,0096SQVDVDSG
UBTF: upstream binding transcription factor, RNA polymerase INP_055048VRPD (220)0,05LKVRPDAT

The bold printed amino acids in the extended cleavage site indicate hits with a G residue at position P2′ detected by the high stringency filter. Numbers in brackets indicate cleavage site position in the amino acid sequence.

Table 4

Analysis of cleavage sites of known non-substrates of granzyme B with GraBCas

Granzyme B non-substrateAcc_numberBest hitScore by GraBCas
TRIM21: 52 kD Ro/SSA autoantigenNP_003132LDPD (294)1,0296
SSA2: 60 kD Ro/SSA autoantigenNP_004591VTTD (427)1,4688
XRCC5: ATP-dependent DNA helicase II Ku80NP_066964FGTD (62)0,3113856
VCL: vinculin isoform VCLNP_003364LQSD (98)0,3167424
VCL: vinculin isoform meta-VCLNP_054706LQSD (98)0,3167424
TUBB2: tubulin, beta 2NP_001060VISD (26)0,0376
CRP: C-reactive protein, pentraxin-relatedNP_000558LSPD (187)1,5444
SERPINA1: serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1NP_000286LAED (26)0,2291328
SERPINA1: serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1NP_001002235LAED (26)0,2291328
SERPINA1: serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1NP_001002236LAED (26)0,2291328
GSTA1: glutathione S-transferase A1NP_665683VEID (61)0,8
PYGB: brain glycogen phosphorylaseNP_002853IEED (129)28,8
TF: transferringNP_001054VTLD (82)0,2592
LTF: lactotransferrinNP_002334VTLD (79)0,2592
LYZ: lysozyme precursorNP_000230RSTD (71)0,0161568
ORM1: orosomucoid 1 precursorNP_000598LAFD (133)0,1145664
F2: coagulation factor II precursor (Thrombin B-chain)NP_000497LDED (306)0,2965248

Numbers in brackets indicate cleavage site position in the amino acid sequence.

Figure 1

Sensitivity–specificity plot for granzyme B. x-axis: scores by the GraBCas program; y-axis: percentage of specificity or sensitivity.

The x-axis of the plots represents the cutoff values (with respect to the PSSM scores), while the y-axis represents the percentage of the specificity or sensitivity of the predictions made by GraBCas, respectively. The specificity is computed as follows: The true negatives are the known non-substrates where the maximal PSSM score of all tetrapeptides ending with a D is smaller than the chosen cutoff value. A specificity of 1 means that all known non-substrates were below the cutoff, i.e. all known non-substrates were correctly classified as negatives. The sensitivity is defined as: where true positives are the known cleavage sites with a score larger than the chosen cutoff value. A sensitivity of 1 means that all cleavage sites of our test set (Table 2) have a score higher than the chosen cutoff and that they have been correctly classified as positives.

RESULTS AND DISCUSSION

We analyzed the cleavage sites of known substrates of granzyme B and caspase 3 to compare the experimentally identified peptide specificity with the cleavage site predicted by the program GraBCas. In total, we collected 29 substrates with 30 cleavage sites for granzyme B (Table 2) and 47 substrates with 59 cleavage sites for caspase 3 (Table 3) and computed the GraBCas scores of the cleavage sites. For granzyme B we collected additionally 17 sequences which are non-substrates of this endopeptidase (Table 4), computed the scores of all putative cleavage sites in these sequences and extracted the best hit by GraBCas for each of these non-substrates.
Table 3

Analysis of cleavage sites of known caspase 3 substrates with GraBCas

Caspase 3 substrateAcc_numberKnown cleavage siteScore by GraBCasP6–P2′ of cleavage site
ADD1: adducing 1 (alpha)NP_001110DDSD (633)0,357TGDDSDAA
APAF1: apoptotic protease activating factorNP_001151SVTD (271)0,462672DKSVTDSV
ARHGDIB: Rho GDP dissociation inhibitor (GDI) betaNP_001166DELD (19)22,4DDDELDSK
ATP2B4: ATPase, Ca++ transporting, plasma membrane 4NP_001675DEID (1080)71,4GLDEIDHA
BAD: BCL2-antagonist of cell deathNP_004313EQED (14)0,001632PSEQEDSS
BAX: BCL2-associated X proteinNP_004315FIQD (33)0,002142QGFIQDRA
BCL2: B-cell CLL/lymphoma 2NP_000624DAGD (34)0,0357EWDAGDVG
BCL2L1: BCL2-like 1NP_001182HLAD (61)0,027846SWHLADSP
BCL2L1: BCL2-like 2NP_001182SSLD (76)0,274176HSSSLDAR
BIRC2: baculoviral IAP repeat-containing 2NP_001157ENAD (372)0,111384GEENADPP
BLM: Bloom syndromeNP_000048TEVD (415)5LLTEVDFN
BRCA1: breast cancer 1, early onsetNP_009225DLLD (1154)3,4272PDDLLDDG
CAMK4: calcium/calmodulin-dependent protein kinase IVNP_001735YWID (31)0,0084966PDYWIDGS
CAMK4: calcium/calmodulin-dependent protein kinase IVNP_001735PAPD (176)0,0144942ATPAPDAP
CDC2L1: cell division cycle 2-like 1 (PITSLRE proteins)NP_001778YVPD (391)0,0124236GDYVPDSP
CDC6: CDC6 cell division cycle 6 homolog (Saccharomyces cerevisiae)NP_001245SEVD (442)4VISEVDGN
CDC6: CDC6 cell division cycle 6 homolog (S.cerevisiae)NP_001245LVRD (99)0,0055692RRLVFDNQ
CDKN1A: cyclin-dependent kinase inhibitor 1A (p21, Cip1)NP_000380DHVD (112)18,7EEDHVDLS
CSEN: calsenilin, presenilin binding protein, EF hand transcription factorNP_038462DSSD (64)0,4284GSDSSDSE
CTNNB1: catenin (cadherin-associated protein), beta 1, 88 kDaNP_001895DLMD (764)0,0153AQDLMDGL
CTNNB1: catenin (cadherin-associated protein), beta 1, 88 kDaNP_001895YPVD (751)10ADYPVDGL
CTNNB1: catenin (cadherin-associated protein), beta 1, 88 kDaNP_001895ADID (83)0,18207QVADIDGQ
CTNNB1: catenin (cadherin-associated protein), beta 1, 88 kDaNP_001895TQFD (115)0,37128PSTQFDAA
CTNNB1: catenin (cadherin-associated protein), beta 1, 88 kDaNP_001895SYLD (32)0,22848QQSYLDSG
DFFA: DNA fragmentation factor, 45 kDa, alpha polypeptideNP_004392DAVD (224)35,7EVDAVDTG
DFFA: DNA fragmentation factor, 45 kDa, alpha polypeptideNP_004392DETD (117)37,8DVDETDSG
DRPLA: dentatorubral-pallidoluysian atrophy (atrophin-1)NP_001931DSLD (109)6,8544DLDSLDGR
EIF2S1: eukaryotic translation initiation factor 2, subunit 1 alpha, 35 kDaNP_004085AEVD (301)1ENAEVDGD
EIF2S1: eukaryotic translation initiation factor 2, subunit 1 alpha, 35 kDaNP_004085DGDD (304)0,0085EVDGDDDA
FNTA: farnesyltransferase, CAAX box, alphaNP_002018VSLD (59)0,137088GFVSLDSP
GCLC: glutamate-cysteine ligase, catalytic subunitNP_001489AVVD (499)0,306GNAVVDGC
GSN: gelsolin (amyloidosis, Finnish type)NP_000168DQTD (403)15,4224DPDQTDGL
HD: huntingtin (Huntington disease)NP_002102DSVD (513)30,6WEAQRDSH
HNRPU: heterogeneous nuclear ribonucleoprotein U (scaffold attachment factor A)NP_004492SALD (100)0,319872GISALDGD
IL16: interleukin 16 (lymphocyte chemoattractant factor)NP_004504SSTD (510)0,462672LNSSTDSA
IL18: interleukin 18 (interferon-gamma-inducing factor)NP_001553LESD (36)0,0014ENLESDYF
KRT18: keratin 18NP_000215VEVD (238)2LTVEVDAP
MAPT: microtubule-associated protein tauNP_005901DMVD (421)0,1SIDMVDSP
MDM2: Mdm2, transformed 3T3 cell double minute 2, p53 binding protein (mouse)NP_002383DVPD (361)12,4236GFDVPDCK
NFKBIA: nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alphaNP_065390DRHD (32)0,3332LDDRHDSG
NUMA1: nuclear mitotic apparatus protein 1NP_006176DSLD (1712)6,8544SIDSLDLS
PAK2: p21 (CDKN1A)-activated kinase 2NP_002568SHVD (212)0,748GDSHVDGA
POLE: polymerase (DNA directed), epsilonNP_006222DQLD (189)9,1392IADQLDNI
POLE: polymerase (DNA directed), epsilonNP_006222DMED (1185)10APDMEDFG
PPP2R1A: protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), alpha isoformNP_055040DEQD (218)1,4ASDEQDSV
PRKCD: protein kinase C, deltaNP_006245DMQD (329)0,0014GEDMQDNS
PRKCM: protein kinase C, muNP_002733CQND (378)5,712AECQNDSG
PRKCQ: protein kinase C, thetaNP_006248DEVD (354)100PLDEVDKM
PRKCZ: protein kinase C, zetaNP_002735DGVD (239)0,0085VIDGMDGI
PRKCZ: protein kinase C, zetaNP_002735EETD (210)1,512PSEETDGI
PRKDC: protein kinase, DNA-activated, catalytic polypeptideNP_008835DEVD (2713)100PGDEVDNK
PSEN2: presenilin 2 (Alzheimer disease 4)NP_000438DSYD (329)4,7124EEDSYDSF
RB1: retinoblastoma 1 (including osteosarcoma)NP_000312DEAD (886)18,2GSDEADGS
RFC1: replication factor C (activator 1) 1, 145 kDaNP_002904DEVD (722)100IMDEVDGM
ROCK1: Rho-associated, coiled-coil containing protein kinase 1NP_005397DETD (1113)37,8SADETDGN
SNRP70: small nuclear ribonucleoprotein 70 kDa polypeptide (RNP antigen)NP_003080DGPD (341)3,451GPDGPDGP
SPTBN1: spectrin, beta, non-erythrocytic 1NP_003119DEVD (1457)100STDEVDSK
SPTBN1: spectrin, beta, non-erythrocytic 2NP_003119ETVD (2146)1,428MAETVDTS
VIM: vimentinNP_003371DSVD (85)30,6KGDEVDGV

The bold printed amino acids in the extended clevage site indicate hits detected by the high stringency filter. Numbers in brackets indicate clevage site position in the amino acid sequence.

The sensitivity–specificity plot for granzyme B is shown in Figure 1. When using a cutoff value of 1.2 in the GraBCas program, we obtain a sensitivity of ∼80% and a specificity of ∼82%. The cutoff value can be adjusted if a higher specificity or sensitivity is needed for the cleavage site prediction. A closer look at the sensitivity–specificity plot shows that the best score (28.8 for IEED in glycogen phosphorylase) of the alleged non-substrates is extremely high. The top value of the best hit IEED is due to the fact that this tetrapeptide has three identical positions with the granzyme B consensus recognition motif IEPD. Furthermore, the amino acid E on P2 has a middle-sized value and the tetrapeptides LEED, IEAD and IETD are known substrates of granzyme B. We assume that glycogen phosphorylase is probably a substrate of granzyme B. This warrants further experimental analysis. We also studied the occurrences of amino acids at position P1′ and P2′ of the known cleavage sites of granzyme B and caspase 3. Additional filtering options have been added to GraBCas that are based on these statistics. For granzyme B, we detected G at position P2′ in 9/30 cleavage sites. This confirms the results of Harris et al. (14), who found for recombinant rat granzyme B a specificity for G at P2′. We did not, however, confirm the proposed total absence of charged amino acids at P1′, in that we found E three times, R two times and K and D one time, each. For caspase 3, we found in total 44/59 (75%) cleavage sites with G, S, A or N at position P1′. These results are in good accordance with the results of Stennicke et al. (15). Absent amino acids included the charged residues R, E, H, K and the large residues Q, I, L, M, F, W and Y. With GraBCas we provide a position specific scoring scheme for the prediction of cleavage sites for granzyme B and caspases 1–9. GraBCas offers an easy to use, concise user interface in register card format. The design of GraBCas specifically acknowledged the high variability of cleavage site recognition sequences. We validated our tool by scoring known substrates and demonstrated its usefulness for protein sequence analysis. GraBCas may contribute to a more comprehensive knowledge of caspase and granzyme B substrates and a better understanding of the biological roles of these enzymes.

SUPPLEMENTARY MATERIAL

Supplementary Material is available at NAR Online.
  15 in total

1.  Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity.

Authors:  L Casciola-Rosen; F Andrade; D Ulanet; W B Wong; A Rosen
Journal:  J Exp Med       Date:  1999-09-20       Impact factor: 14.307

Review 2.  Caspases: more than just killers?

Authors:  M Los; C Stroh; R U Jänicke; I H Engels; K Schulze-Osthoff
Journal:  Trends Immunol       Date:  2001-01       Impact factor: 16.687

Review 3.  Apoptosis-independent functions of killer caspases.

Authors:  Alicia Algeciras-Schimnich; Bryan C Barnhart; Marcus E Peter
Journal:  Curr Opin Cell Biol       Date:  2002-12       Impact factor: 8.382

4.  Direct cleavage of the human DNA fragmentation factor-45 by granzyme B induces caspase-activated DNase release and DNA fragmentation.

Authors:  E Sharif-Askari; A Alam; E Rhéaume; P J Beresford; C Scotto; K Sharma; D Lee; W E DeWolf; M E Nuttall; J Lieberman; R P Sékaly
Journal:  EMBO J       Date:  2001-06-15       Impact factor: 11.598

5.  DFF45/ICAD can be directly processed by granzyme B during the induction of apoptosis.

Authors:  D A Thomas; C Du; M Xu; X Wang; T J Ley
Journal:  Immunity       Date:  2000-06       Impact factor: 31.745

Review 6.  Toward computer-based cleavage site prediction of cysteine endopeptidases.

Authors:  Tobias Lohmüller; Daniel Wenzler; Sascha Hagemann; Wolfgang Kiess; Christoph Peters; Thomas Dandekar; Thomas Reinheckel
Journal:  Biol Chem       Date:  2003-06       Impact factor: 3.915

7.  Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells.

Authors:  J W Heusel; R L Wesselschmidt; S Shresta; J H Russell; T J Ley
Journal:  Cell       Date:  1994-03-25       Impact factor: 41.582

8.  Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B.

Authors:  A J Darmon; D W Nicholson; R C Bleackley
Journal:  Nature       Date:  1995-10-05       Impact factor: 49.962

9.  Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation.

Authors:  V R Sutton; J E Davis; M Cancilla; R W Johnstone; A A Ruefli; K Sedelies; K A Browne; J A Trapani
Journal:  J Exp Med       Date:  2000-11-20       Impact factor: 14.307

Review 10.  Many cuts to ruin: a comprehensive update of caspase substrates.

Authors:  U Fischer; R U Jänicke; K Schulze-Osthoff
Journal:  Cell Death Differ       Date:  2003-01       Impact factor: 15.828

View more
  44 in total

1.  ApoptoProteomics, an integrated database for analysis of proteomics data obtained from apoptotic cells.

Authors:  Magnus Ø Arntzen; Bernd Thiede
Journal:  Mol Cell Proteomics       Date:  2011-11-08       Impact factor: 5.911

2.  Prediction of protease substrates using sequence and structure features.

Authors:  David T Barkan; Daniel R Hostetter; Sami Mahrus; Ursula Pieper; James A Wells; Charles S Craik; Andrej Sali
Journal:  Bioinformatics       Date:  2010-05-26       Impact factor: 6.937

3.  Twenty years of bioinformatics research for protease-specific substrate and cleavage site prediction: a comprehensive revisit and benchmarking of existing methods.

Authors:  Fuyi Li; Yanan Wang; Chen Li; Tatiana T Marquez-Lago; André Leier; Neil D Rawlings; Gholamreza Haffari; Jerico Revote; Tatsuya Akutsu; Kuo-Chen Chou; Anthony W Purcell; Robert N Pike; Geoffrey I Webb; A Ian Smith; Trevor Lithgow; Roger J Daly; James C Whisstock; Jiangning Song
Journal:  Brief Bioinform       Date:  2019-11-27       Impact factor: 11.622

4.  Immunogenicity of autoantigens.

Authors:  Christina Backes; Nicole Ludwig; Petra Leidinger; Christian Harz; Jana Hoffmann; Andreas Keller; Eckart Meese; Hans-Peter Lenhof
Journal:  BMC Genomics       Date:  2011-07-04       Impact factor: 3.969

5.  Granzyme B Cleaves Multiple Herpes Simplex Virus 1 and Varicella-Zoster Virus (VZV) Gene Products, and VZV ORF4 Inhibits Natural Killer Cell Cytotoxicity.

Authors:  Chelsea Gerada; Megan Steain; Tessa Mollie Campbell; Brian McSharry; Barry Slobedman; Allison Abendroth
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

6.  High resolution quantitative proteomics of HeLa cells protein species using stable isotope labeling with amino acids in cell culture(SILAC), two-dimensional gel electrophoresis(2DE) and nano-liquid chromatograpohy coupled to an LTQ-OrbitrapMass spectrometer.

Authors:  Bernd Thiede; Christian J Koehler; Margarita Strozynski; Achim Treumann; Robert Stein; Ursula Zimny-Arndt; Monika Schmid; Peter R Jungblut
Journal:  Mol Cell Proteomics       Date:  2012-10-01       Impact factor: 5.911

7.  A sequence and structure based method to predict putative substrates, functions and regulatory networks of endo proteases.

Authors:  Prasanna Venkatraman; Satish Balakrishnan; Shashidhar Rao; Yogesh Hooda; Suyog Pol
Journal:  PLoS One       Date:  2009-05-27       Impact factor: 3.240

8.  Pripper: prediction of caspase cleavage sites from whole proteomes.

Authors:  Mirva Piippo; Niina Lietzén; Olli S Nevalainen; Jussi Salmi; Tuula A Nyman
Journal:  BMC Bioinformatics       Date:  2010-06-15       Impact factor: 3.169

9.  Cleavage of the Junin virus nucleoprotein serves a decoy function to inhibit the induction of apoptosis during infection.

Authors:  Svenja Wolff; Stephan Becker; Allison Groseth
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

10.  A multi-factor model for caspase degradome prediction.

Authors:  Lawrence J K Wee; Joo Chuan Tong; Tin Wee Tan; Shoba Ranganathan
Journal:  BMC Genomics       Date:  2009-12-03       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.